ArticleScientific reports2018

Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.

Raquel Frenedoso da Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.